Which should you choose? Here's what you need to know.
Cagrilintide has Phase 3 human data and is the amylin half of CagriSema. 5-Amino-1MQ has an interesting NNMT inhibition mechanism but only preclinical evidence.
5-Amino-1MQ blocks NNMT to boost fat cell energy expenditure. Mouse studies showed significant reversal of diet-induced obesity, but no human clinical trials have been conducted.
Choose 5-Amino-1MQ if:
You're looking for a non-hormonal fat-burning approach and are comfortable with preclinical-only evidence.
Cagrilintide is a long-acting amylin receptor agonist in Phase 3 trials. Combined with semaglutide as CagriSema, it produced 20.4% weight loss with a favorable GI side effect profile.
Choose Cagrilintide if:
You want a peptide with real human clinical data targeting appetite through the amylin pathway.
Once you've decided which peptide fits your needs, here's how they compare on price and vendor options.
Our top-rated vendor for each, based on trust scores, purity testing, and price.
We re-check vendor prices continuously and score vendors on Finnrick blind-test results — samples bought anonymously and sent to a lab, not vendor claims. No vendor can pay to rank higher. See our full methodology.